The optimisations of all the crystal structures and the minimisations of their lattice energies were performed using the GRACE software package, version 1.6. 1 This software calculates DFT energies using VASP 4.6 2,3 and implements a correction for the van der Waals energy. 4 Projector augmented wave (PAW) potentials and the PW91 exchange-correlation functional with the Vosko, Wilk, and Nusair interpolation formula were used for DFT calculations. The plane-wave cut-off energy was set at 520 eV. The k-point spacing in the Brillouin zone was approximately 0.7 Å -1 . The wave function convergence level was 0.5 × 10 -6 kcal·mol -1 per atom. The van der Waals correction is expressed as a pair-wise sum over all atoms. 4 The C 6 coefficients of the van der Waals correction have been parameterised using experimental dipole oscillator strength distribution data. Minimisations were complete when the change in lattice energy was no more than 0.25 × 10 -3 kcal·mol -1 per atom, atomic displacements were no more than 3 × 10 -3 Å, and maximum atomic forces were no more than 0.7 kcal·Å -1 ·mol -1 per atom.
ethanol solution, 6 whilst its β polymorph was prepared in a sublimation process at 403 K at reduced pressure. 7 For adipic acid, form I is the stable phase above 136 K and it transforms into form II below 136 K. 8 An additional form III was prepared by solvent evaporation at room temperature, but its structure was determined at 100 K. 9 The DFT-D results suggest (see Table S1 ) that form III is the most stable form, followed by forms II and I. A phase transition of heptadecanoic acid from form B to form C at 331 K was determined by DSC and powder X-ray diffraction, prior to melting at 333 K. 10 Form II of rac-ibuprofen 11 and the monoclinic polymorph of DL-mandelic acid 12 were reported as metastable phases. The monoclinic polymorph of 3-hydroxybenzoic acid was concluded to be the more stable form via a series of solubility tests and studies of heat capacities at different temperatures. 13 The β polymorphs of alkanedicarboxylic acids are the stable forms at room temperature, followed by phase transitions to α forms at high temperatures. 14 However, the DFT-D results suggest that the α forms are more stable. The atomic coordinates for the α form of glutaric acid are not known and only its unit cell parameters are available, hence it could not be considered in this study. 15 Experimentally, at 56 K the β form of malonic acid transforms into the γ form, which has two independent molecules in the asymmetric unit. 16 However, the DFT-D optimised γ form becomes a Z' = 1 structure and converges to the same minimum as the optimised β form. For isonicotinamide, the order of polymorph stability from DSC results is form I > Iso3 > form II. 5 The DFT-D results suggest a stability order of form II > form I > Iso3. For carbamazepine, the order of polymorph stability from DSC results is form III > form I > form IV > form II. 17 In agreement with experiment, the DFT-D results indicate that form III is the most stable phase, whilst form II is the least stable. The calculated stability order for forms I and IV, however, is not in agreement with the DSC data, although the energy difference between these two forms is only 0.04 kcal·mol -1 . For 3,5dinitrobenzoic acid, the relative stabilities of its polymorphs have not been reported. Table S1 : DFT-D lattice energies of the pure co-formers in nicotinamide, isonicotinamide and picolinamide co-crystals and salts reported in the CSD version 5.32. The most stable polymorph of each compound is given in bold.
Compound name
Molecular formula CSD reference code [a] Polymorph type E DFT-D [a] CSD = Cambridge Structural Database. 18 [b] E DFT-D is the minimised lattice energy per mole of molecule, calculated by the DFT-D method. Numbers in brackets refer to the energy differences relative to the most stable polymorph, which is given in bold face.
[c] The root-mean-squared atomic displacement after optimisation, in comparison to the experimental structure, excluding hydrogen atoms.
[d] Missing hydrogen atoms in the experimental structures were added manually prior to DFT-D optimisation.
[e] The position of a COOH proton was edited prior to DFT-D optimisation.
[f] The structure was converted from the P112 1 /c space group into P2 1 /c prior to DFT-D optimisation.
[g] For structures with disordered atoms, every possible starting configuration was DFT-D optimised and the most stable results are shown.
[h] The CSD contains another norfloxacin structure, VETVOG01, which was later discovered to be a sesquihydrate 19 and therefore not considered in this study.
DFT-D lattice energies and calculated stabilities of co-crystals and salts
81 co-crystals involving nicotinamide and isonicotinamide, 3 hybrid salt co-crystals of isonicotinamide, and 18 salts involving nicotinamide, isonicotinamide and picolinamide were optimised by the DFT-D method. Their lattice energies are expressed in kcal·mol -1 per mole of formula unit and their stabilities are calculated relative to the most stable (as determined by the DFT-D method) polymorphs of their pure component co-formers. The results are reported in Table S2 . [a] CSD = Cambridge Structural Database. 18 [b] E DFT-D is the minimised lattice energy of a co-crystal (or a salt) calculated by the DFT-D method and is expressed in kcal per mole of formula unit which consist of two or more co-former molecules in a fixed stoichiometric ratio.
[c] ΔE is the calculated energy change in forming a co-crystal or salt from the most stable polymorphs of the pure co-formers. 
Lattice energy minimisations of 24 alternative celecoxib:nicotinamide co-crystal structures
The experimental co-crystal structure of VIGDAR 20 reports disordered fluorine atoms, which were rationalised before DFT-D optimisation. The reported crystal structure also possesses unoccupied hydrogen bonding sites and has S=O bond lengths of 1.596 and 1.405 Å. In addition, the reported C=O bond of the nicotinamide amide group is longer than its C-N bond. 24 variations of the celecoxib:nicotinamide co-crystal packing were investigated by altering the molecular conformations, including; rotation of the pyridine ring by 180° (2 conformations), rotation of the nicotinamide amide group by 180° (2 conformations), rotation of the sulfonamide group by 120° (3 conformations) and consideration of the disordered trifluoromethyl group (2 conformations) in celecoxib. All 24 (2x2x3x2) structures were optimised with the DFT-D method and converged to 12 distinct structures. Both starting conformations of the trifluoromethyl group, Pos_a and Pos_b, always led to the same optimised structure. Rotating the pyridine ring by 180˚, in general, led to less stable structures, except for those with conformer_10a and conformer_10b (see Table S3 ), in which intermolecular hydrogen bonds were formed between the pyridine ring and the sulfonamide during the optimisations. Structures with conformer_5a and conformer_5b involve a rotation of the amide group by 180˚ in nicotinamide and an anti-clockwise rotation of the sulfonamide group by 120˚ in celecoxib (viewing along the S-C bond), which facilitates hydrogen bonding between the two molecules. These two structures converged to the most stable structure of all. Note that in both conformer_5a and conformer_5b, the nitrogen atom of the amide group of nicotinamide occupies a position which corresponds to the amide oxygen in the reported VIGDAR structure, whilst the nitrogen atom of the sulfonamide group of celecoxib occupies a position which corresponds to the sulfonyl oxygen with the longer S=O bond in the reported VIGDAR structure. Hence, based on these geometric comparisons and lattice energy considerations, we are confident that the real co-crystal structure of celecoxib and nicotinamide corresponds to the optimised structure with conformer_5a or conformer_5b, except that the trifluoromethyl group is disordered. Note that this most stable co-crystal structure is still 0.36 kcal·mol -1 less stable than the separate nicotinamide and celecoxib structures. This small energy difference is, at least in part, due to the stabilising effect of the disordered trifluoromethyl group, which is not taken into account in the lattice energy calculations. A cif containing the proposed celecoxib:nicotinamide co-crystal structure is provided as a separate file. Table S3 : Effect of 24 variations in molecular conformations in the celecoxib:nicotinamide 1:1 co-crystal structure on the DFT-D minimised lattice energy. The structure with conformer_1a corresponds to the structure reported in the CSD with reference code VIGDAR. 20 Starting conformation Fluorine atoms [a] Pyridine ring [b] Amide group [c] Sulfonamide [ a] "Pos_a" and "Pos_b" stand for the positions of the fluorine atoms without and with the label "?" in the cif file, respectively. [b] "+0°" stands for the conformation of the pyridine ring in the original structure, whilst "+180°" represents a rotation by 180°. [c] "+0°" stands for the conformation of the amide group in the original structure, whilst "+180°" represents a rotation by 180°. [d] "+0°" stands for the conformation of the sulfonamide group in the original structure, whilst "+120°" and "+240°" represent rotations by 120° and 240° respectively in an anti-clockwise direction, viewing along the S-C bond.
[e] E DFT-D is the minimised lattice energy of the co-crystal calculated by the DFT-D method and is expressed in kcal per mole of building blocks which consist of one nicotinamide molecule and one celecoxib molecule.
[f] ΔE is the difference in lattice energy between an optimised co-crystal structure and the sum of lattice energies of nicotinamide (E DFT-D of NICOAM01 in Table 1 ) and celecoxib (E DFT-D of DIBBUL in Table 1 ).
